Last updated on

Journal of Clinical Oncology
Research Hotspot & Journal Scope - cancer


Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.8503
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

David J. Kwiatkowski · Valerie W. Rusch · Jamie E. Chaft · Bruce E. Johnson · Alan Nicholas · Ignacio Ivan Wistuba · Robert E. Merritt · Jay M. Lee · Paul A. Bunn · Yan Tang · See-Chun Phan · Saiama N. Waqar · Alexander Patterson · Eric B. Haura · Eric M. Toloza · Karen L. Reckamp · Dan J. Raz · Katja Schulze · Ann M. Johnson · David P. Carbone ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.18.02309
Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial

Yanhong Deng · Pan Chi · Ping Lan · Lei Wang · Weiqing Chen · Long Cui · Daoda Chen · Jie Cao · Hongbo Wei · Xiang Peng · Zonghai Huang · Guanfu Cai · Ren Zhao · Zhongcheng Huang · Lin Xu · Hongfeng Zhou · Yisheng Wei · Hao Zhang · Jian Zheng · Yan Huang · Zhiyang Zhou · Yue Cai · Liang Kang · Meijin Huang · Xiaojian Wu · Junsheng Peng · Donglin Ren · Jianping Wang ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.5005
TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations

Joaquin Mateo · Nuria Porta · U. McGovern · Tony Elliott · Robert Jones · Isabel Syndikus · Christy Ralph · Suneil Jain · Mohini Varughese · O. Parikh · Simon J. Crabb · Susana Miranda · George Seed · Claudia Bertan · Aude Espinasse · Peter Chatfield · Diletta Bianchini · Emma Hall · Suzanne Carreira · Johann S. de Bono ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.6018
Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.

Matthew H. Taylor · Justin F. Gainor · Mimi I-Nan Hu · Viola W. Zhu · Gilberto Lopes · Sophie Leboulleux · Marcia S. Brose · Martin Schuler · Daniel W. Bowles · Dong-Wan Kim · Christina S. Baik · Elena Garralda · Chia-Chi Lin · Douglas Adkins · Debashis Sarker · Giuseppe Curigliano · Hui Zhang · Corinne Clifford · Christopher D. Turner · Vivek Subbiah ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.1005
Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.

Robert Hugh Jones · Margherita Carucci · Angela C. Casbard · Rachel Butler · Fouad S Alchami · Catherine Jane Bale · Pavel Bezecny · Johnathan Joffe · Sarah Moon · Chris Twelves · Ramachandran Venkitaraman · Simon Waters · Sacha J Howell ·

Medicine
PDF

Patients and methods Of the patients with HCC enrolled the Korean Central Cancer Registry from 2008 to 2014, the Korean Liver Cancer Study Group randomly extracted 10,580 patient data from ~50 hospitals nationwide.

Role of local treatment including radiotherapy in Barcelona Clinic of Liver Cancer stage C patients: a nationwide cohort analysis in South Korea [10.2147/CMAR.S193761]


Our objective is to investigate the efficacy of using MR-guided laser focal therapy for MR-visible prostate cancer utilizing a transrectal approach for laser applicator placement and therapy delivery in an outpatient setting.

MP78-17 A PHASE II STUDY TO EVALUATE OUTPATIENT, TRANSRECTALLY-DELIVERED, MRI-GUIDED LASER FOCAL THERAPY OF PROSTATE CANCER: 9 YEAR INTERIM RESULTS (NCT 02243033) [10.1097/01.JU.0000557349.47574.70]


In addition to CRC, the screening of duodenal cancer and desmoid tumors should be routinely performed to prevent the mortality.

Clinical Management of Hereditary Colorectal Cancer [10.1007/978-981-13-3050-6_11]


5% of all new cancer diagnoses.

Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone. [10.1358/dot.2019.55.1.2914339]


Herein we have designed a new type of hybrid particles and evaluated its potential to be used in image-guided cancer diagnosis and therapy without the need of any toxic anticancer or contrast agents.

Magnetic/Gold Core-Shell Hybrid Particles for Targeting and Imaging-Guided Photothermal Cancer Therapy. [10.1166/jbn.2019.2839]


Highly Related Keywords from cancer

Research Hotspot

Journal of Clinical Oncology

Research Hotspot
Journal of Clinical Oncology Related Journals

Popular Journals